- Amicus Therapeutics (NASDAQ:FOLD) is up 2% after hours on average volume in response to its announcement that Health Canada has approved Galafold (migalastat) for the treatment of Fabry disease.
- The company says the product will be available to patients in the coming weeks.
Amicus' Galafold OK'd in Canada; shares up 2% after hours
Recommended For You
About FOLD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
FOLD | - | - |
Amicus Therapeutics, Inc. |